{"disease":{"id":"lymphoid-hematological-malignancies","name":"lymphoid hematological malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02223598","title":"A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":120,"lead_sponsor_name":"Cleave Biosciences, Inc.","has_results":false},{"nct_id":"NCT04283006","title":"A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"He Huang","has_results":false},{"nct_id":"NCT07472972","title":"Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT00788684","title":"Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04626908","title":"Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"He Huang","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}